Fierce Biotech34m
KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal
As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...